{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:05:23Z","timestamp":1791475523812,"version":"4.3.4"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005866","name":"Far Eastern Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jgar.2026.06.021","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:39:32Z","timestamp":1783010372000},"page":"226-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Aztreonam-avibactam and cefiderocol against metallo-\u03b2-lactamase-producing Enterobacterales and other carbapenem-resistant Gram-negative pathogens: Microbiological activity and clinical evidence"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Chung","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tsung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ren","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shio-Shin","family":"Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2026.06.021_bib0001","article-title":"Antimicrobial resistance: a growing serious threat for global public health","volume":"11","author":"Salam","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.jgar.2026.06.021_bib0002","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jmii.2025.01.006","volume":"58","author":"Lee","year":"2025","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2026.06.021_bib0003","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/S2666-5247(22)00329-9","article-title":"Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study","volume":"4","author":"Reyes","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.jgar.2026.06.021_bib0004","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1080\/14787210.2024.2412637","article-title":"Potentially effective antimicrobial treatment for pneumonia caused by isolates of carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii complex species: what can we expect in the future?","volume":"22","author":"Jean","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2026.06.021_bib0005","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3390\/ph14040370","volume":"14","author":"Nguyen","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jgar.2026.06.021_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107363","volume":"64","author":"Jean","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.06.021_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106380","volume":"90","author":"Jean","year":"2025","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2026.06.021_bib0008","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1128\/AAC.21.6.950","article-title":"Mode of action of azthreonam","volume":"21","author":"Georgopapadakou","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0009","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00000441-199107000-00011","article-title":"Aztreonam: a review of the first monobactam","volume":"302","author":"Westley-Horton","year":"1991","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jgar.2026.06.021_bib0010","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1128\/AAC.39.1.192","article-title":"Kinetic analysis of extension of substrate specificity with Xanthomonas maltophilia, Aeromonas hydrophila, and Bacillus cereus metallo-beta-lactamases","volume":"39","author":"Felici","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0011","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/AAC.02102-15","article-title":"Distinctive binding of avibactam to penicillin-binding proteins of gram-negative and gram-positive bacteria","volume":"60","author":"Asli","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0012","doi-asserted-by":"crossref","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-lactam-\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2026.06.021_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2025.107500","volume":"66","author":"Jean","year":"2025","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.06.021_bib0014","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 16.0 2026. Available at: https:\/\/www.eucast.org\/clinical_breakpoints. Accessed 13 May 2026."},{"key":"10.1016\/j.jgar.2026.06.021_bib0015","series-title":"Performance standards for antimicrobial susceptibility testing\u2014thirty-sixth edition: M100","year":"2026"},{"key":"10.1016\/j.jgar.2026.06.021_bib0017","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/jac\/23.3.401","article-title":"The pharmacokinetics of aztreonam and penetration into the bronchial secretions of critically ill patients","volume":"23","author":"Boccazzi","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0018","unstructured":"Ceftazidime-avibactam plasma levels in critically ill patients, including those receiving continuous renal replacement therapy. NCT04358991. Accessed via: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj https:\/\/cdn.clinicaltrials.gov\/large-docs\/91\/NCT04358991\/Prot_SAP_000.pdf. Last access on 28 May 2026."},{"key":"10.1016\/j.jgar.2026.06.021_bib0019","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1093\/jac\/dkaf375","article-title":"Global susceptibility profiles and potential resistance mechanisms of ceftazidime-avibactam-resistant, non-carbapenemase-producing carbapenem-resistant enterobacterales: 2020-23 data from the Antimicrobial Testing Leadership and Surveillance","volume":"80","author":"Lai","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0020","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile beta-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2026.06.021_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01090-21","article-title":"Recent emergence of aztreonam-avibactam resistance in NDM and OXA-48 carbapenemase-producing Escherichia coli in Germany","volume":"65","author":"Nordmann","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00472-17","article-title":"In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0023","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jgar.2021.01.010","article-title":"Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012-2017","volume":"24","author":"Estabrook","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2026.06.021_bib0024","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1093\/jac\/dkab279","article-title":"Investigation of mechanisms responsible for decreased susceptibility of aztreonam\/avibactam activity in clinical isolates of enterobacterales collected in Europe, Asia and Latin America in 2019","volume":"76","author":"Mendes","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107256","article-title":"Resistance to aztreonam-avibactam among clinical isolates of Escherichia coli is primarily mediated by altered penicillin-binding protein 3 and impermeability","volume":"64","author":"Tellapragada","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.06.021_bib0026","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s10096-024-04958-w","article-title":"In vivo development of resistance to novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series","volume":"43","author":"Boattini","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.021_bib0027","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaf131","article-title":"Aztreonam-avibactam for the treatment of serious infections caused by metallo-\u03b2-lactamase-producing gram-negative pathogens: a phase 3 randomized trial (ASSEMBLE)","volume":"7","author":"Daikos","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jgar.2026.06.021_bib0028","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial","volume":"25","author":"Carmeli","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.021_bib0029","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s40262-021-01063-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of cefiderocol","volume":"60","author":"Bilal","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2026.06.021_bib0030","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2026.06.021_bib0031","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/jac\/dkab015","article-title":"Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant gram-negative bacterial infections","volume":"76","author":"Parsels","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0032","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria","volume":"62","author":"Ito","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0033","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.04936-22","article-title":"In vitro activity of cefiderocol compared to other antimicrobials against a collection of metallo-beta-lactamase-producing gram-negative bacilli from southern Spain","volume":"11","author":"Delgado-Valverde","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2026.06.021_bib0034","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaa060","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible gram-negative bacteria from Europe","volume":"2","author":"Longshaw","year":"2020","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jgar.2026.06.021_bib0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1089\/mdr.2022.0279","article-title":"In vitro activity of cefiderocol against meropenem-nonsusceptible gram-negative bacilli with defined \u03b2-lactamase carriage: SIDERO-WT surveillance studies, 2014-2019","volume":"29","author":"Wise","year":"2023","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2026.06.021_bib0036","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2024.05.009","article-title":"In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance","volume":"38","author":"Kayama","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2026.06.021_bib0037","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00569-23","article-title":"In vitro activities and inoculum effects of cefiderocol and aztreonam-avibactam against metallo-\u03b2-lactamase-producing Enterobacteriaceae","volume":"11","author":"Huang","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2026.06.021_bib0038","article-title":"In vitro activity of cefiderocol and comparators against carbapenem-resistant gram-negative pathogens from France and Belgium","volume":"11","author":"Oueslati","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2026.06.021_bib0039","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dky425","volume":"74","author":"Hsueh","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0040","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/jac\/dkad396","article-title":"In vitro activity of cefiderocol against a global collection of carbapenem-resistant Pseudomonas aeruginosa with a high level of carbapenemase diversity","volume":"79","author":"Gill","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0041","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01474-24","volume":"12","author":"Kimbrough","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2026.06.021_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107378","article-title":"Acquired blaCfxA-3 carried by a conjugative transposon or duplicated intrinsic blaCME-3 mediates cefiderocol resistance in Elizabethkingia anophelis clinical isolates","volume":"64","author":"Yang","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.06.021_bib0043","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00093-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study)","volume":"61","author":"Hackel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0044","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00346-23","article-title":"In vitro and in vivo activity of cefiderocol against Achromobacter spp. And Burkholderia cepacia complex, including carbapenem-non-susceptible isolates","volume":"67","author":"Takemura","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0045","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00685-20","article-title":"Burkholderia pseudomallei clinical isolates are highly susceptible in vitro to cefiderocol, a siderophore cephalosporin","volume":"65","author":"Burnard","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.04.016","article-title":"Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC \u03b2-lactamase mutants and the inoculum effect","volume":"27","author":"Hobson","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2026.06.021_bib0047","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1473-3099(25)00477-3","article-title":"NDM-driven cefiderocol resistance: effect and therapeutic considerations","volume":"25","author":"Warecki","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.021_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(26)00008-3","article-title":"Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance","volume":"26","author":"Warecki","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.021_bib0049","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.01779-21","article-title":"In vitro evolution of cefiderocol resistance in an NDM-producing Klebsiella pneumoniae due to functional loss of CirA","volume":"9","author":"McElheny","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2026.06.021_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2025.107553","article-title":"Susceptibility to new antibiotics and genetic characterisation of carbapenemase-producing enterobacterales: low activity of cefiderocol against NDM-producing isolates","volume":"66","author":"Fax\u00e9n","year":"2025","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.06.021_bib0051","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00097-18","article-title":"TonB-dependent receptor repertoire of Pseudomonas aeruginosa for uptake of siderophore-drug conjugates","volume":"62","author":"Luscher","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0052","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01221-20","article-title":"Cefiderocol resistance in Acinetobacter baumannii: roles of \u03b2-lactamases, siderophore receptors, and penicillin binding protein 3","volume":"64","author":"Malik","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0053","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00084-22","article-title":"Emergence of high-level cefiderocol resistance in carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in patients with hematologic malignancies in China","volume":"10","author":"Lan","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2026.06.021_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2022.11.014","article-title":"Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients","volume":"29","author":"L\u00f3pez-Causap\u00e9","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2026.06.021_bib0055","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkaf462","article-title":"In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes","volume":"81","author":"Raro","year":"2026","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0056","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3201\/eid3101.241426","article-title":"Cefiderocol resistance conferred by plasmid-located ferric citrate transport system in KPC-producing Klebsiella pneumoniae","volume":"31","author":"Polani","year":"2025","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.021_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2025.1719798","article-title":"Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens","volume":"16","author":"Sartori","year":"2026","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2026.06.021_bib0058","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00887-25","article-title":"Optimizing target inactivation to treat multidrug-resistant Escherichia coli with NDM and PBP3 mutations: \"going the extra mile\"","volume":"70","author":"Fabrizio","year":"2026","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0059","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00053-26","article-title":"Case commentary: when one target is not enough-PBP3 insertions and target redundancy in Escherichia coli","volume":"70","author":"Stellfox","year":"2026","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0060","doi-asserted-by":"crossref","first-page":"7177","DOI":"10.2147\/IDR.S392241","article-title":"Resistance to cefiderocol involved expression of PER-1 \u03b2-lactamase and downregulation of iron transporter system in carbapenem-resistant Acinetobacter baumannii","volume":"15","author":"He","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2026.06.021_bib0061","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-17044-8","article-title":"Exploring mutational possibilities of KPC variants to reach high level resistance to cefiderocol","volume":"15","author":"Hanna","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgar.2026.06.021_bib0062","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/cid\/ciab888","article-title":"Progressive development of cefiderocol resistance in Escherichia coli during therapy is associated with an increase in blaNDM-5 copy number and gene expression","volume":"75","author":"Simner","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.021_bib0063","doi-asserted-by":"crossref","first-page":"1503.e1","DOI":"10.1016\/j.cmi.2022.06.018","article-title":"Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales","volume":"28","author":"Danjean","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2026.06.021_bib0064","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s40121-025-01147-w","article-title":"From clinical trials to real-world experiences: evidence about cefiderocol use and potential role in empirical therapy","volume":"14","author":"Russo","year":"2025","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2026.06.021_bib0065","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciab511","article-title":"Rapid development of cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cirA","volume":"74","author":"Klein","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.021_bib0066","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01009-23","article-title":"The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy","volume":"68","author":"Teran","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0067","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41429-024-00762-y","article-title":"In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol","volume":"77","author":"Kriz","year":"2024","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.jgar.2026.06.021_bib0068","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(21)00194-8","article-title":"Widespread cefiderocol heteroresistance in carbapenem-resistant gram-negative pathogens","volume":"21","author":"Choby","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.021_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(21)00271-8","article-title":"Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?","volume":"2","author":"Choby","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.jgar.2026.06.021_bib0070","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.021_bib0071","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s40262-021-01063-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of cefiderocol","volume":"60","author":"Bilal","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2026.06.021_bib0072","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.021_bib0073","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.021_bib0074","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlad085","article-title":"Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. baumannii ventilator-associated pneumonia: a propensity-weighted cohort study","volume":"5","author":"Rando","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jgar.2026.06.021_bib0075","article-title":"Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis","volume":"63","author":"Gatti","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.06.021_bib0076","article-title":"Effectiveness of first-line therapy with old and novel antibiotics in ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii: a real life, prospective, observational, single-center study","volume":"12","author":"Dalfino","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2026.06.021_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106825","article-title":"Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19","volume":"62","author":"Russo","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.06.021_bib0078","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jgar.2021.10.014","volume":"27","author":"Gatti","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2026.06.021_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106852","article-title":"Pharmacokinetics\/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF)","volume":"62","author":"Gatti","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.06.021_bib0080","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s10096-025-05108-6","article-title":"Effectiveness and safety of cefiderocol treatment in patients with gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study","volume":"44","author":"Torre-Cisneros","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.021_bib0081","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00194-23","article-title":"Cefiderocol treatment for patients with multidrug- and carbapenem-resistant Pseudomonas aeruginosa infections in the compassionate use program","volume":"67","author":"Satlin","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.06.021_bib0082","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/cid\/ciad725","article-title":"Clinical features and outcomes of infections caused by metallo-\u03b2-lactamase-producing enterobacterales: a 3-year prospective study from an endemic area","volume":"78","author":"Falcone","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.021_bib0083","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03108-23","article-title":"Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections","volume":"12","author":"El Ghali","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2026.06.021_bib0084","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/cid\/ciac078","article-title":"Cefiderocol for the treatment of infections due to metallo-beta-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies","volume":"75","author":"Timsit","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.021_bib0085","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3390\/antibiotics13090874","article-title":"Cefiderocol for the treatment of infections by VIM-type-producing gram-negative bacteria","volume":"13","author":"Kirkegaard-Biosca","year":"2024","journal-title":"Antibiotics (Basel)"},{"issue":"Supplement_1","key":"10.1016\/j.jgar.2026.06.021_bib0086","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.1699","article-title":"Two against one: ceftazidime-avibactam plus aztreonam vs cefiderocol in the treatment of metallo-beta-lactamase-producing bacterial infections","volume":"12","author":"Harris","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2026.06.021_bib0087","series-title":"Proceedings of the ESCMID Global 2025. Congress of the European Society of Clinical Microbiology and Infectious Diseases","article-title":"P\u201304319. Ceftazidime-avibactam plus aztreonam versus cefiderocol in the treatment of infections caused by metallo-\u03b2-lactamase-producing microorganisms: real-word data from the Italian cohort SUSANA","author":"Mezzadri","year":"2025"},{"key":"10.1016\/j.jgar.2026.06.021_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106376","article-title":"Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant gram-negative bacteria: CEFI-ID","volume":"90","author":"Soueges","year":"2025","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2026.06.021_bib0089","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/jac\/dkad298","article-title":"Cefiderocol use for the treatment of infections by carbapenem-resistant gram-negative bacteria: an Italian multicentre real-life experience","volume":"78","author":"Piccica","year":"2023","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:50:51Z","timestamp":1790178651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716526001025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":88,"alternative-id":["S2213716526001025"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2026.06.021","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aztreonam-avibactam and cefiderocol against metallo-\u03b2-lactamase-producing Enterobacterales and other carbapenem-resistant Gram-negative pathogens: Microbiological activity and clinical evidence","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2026.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}